Drugs / JNJ-87189401
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06095089 | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-87189401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06095089 ↗ |
| Target | CD28 | “JNJ-87189401 (PSMA-CD28 Bispecific Antibody)” NCT06095089 ↗ |